The phenotype of ascitic fluid lymphocytes in patients with ovarian carcinoma and other primaries

Onkologie

Volumn 24, Issue 2, 2001, Pages 156-160

  Melichar, B ^a   Touskova M ^a   Tosner J ^a   Kopecky O ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Ascites; Interleukin 10; Neopterin; Tumor infiltrating lymphocytes

Indexed keywords

CD19 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; FAS ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; NEOPTERIN;

ADULT; AGED; ARTICLE; ASCITES FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; INTESTINE CANCER; LIVER METASTASIS; MALE; MELANOMA; NATURAL KILLER CELL; OVARY CANCER; PANCREAS CANCER; PHENOTYPE; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ASCITIC FLUID; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-10; KILLER CELLS, NATURAL; LIVER NEOPLASMS; LYMPHATIC METASTASIS; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPTERIN; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PROGNOSIS; SKIN NEOPLASMS;

EID: 17544396862     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050304     Document Type: Article

References (26)

1. van de Molengraft FJJM, Vooijs GP Survival of patients with malignancy-associated effusions. Acta Cytol 1989;6:911-916.
2. Zeimet AG, Widschwendter M, Knabbe C, Fuchs D, Herold M, Muller-Holzner E, Daxenbichler G, Offner FA, Dapunt O, Marth C Ascitic interleukin12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 1998;16:1861-1868.
3. Topalian SL, Solomon D, Rosenberg SA Tumorspecific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989;142:3714-3725.
4. Aebersold P, Hyatt C, Johnson S, Hines H, Korcak L, Sanders M, Lotze M, Topalian S, Yang J, Rosenberg SA Lysis of autologous melanoma cells by tumorinfiltrating lymphocytes: Association with clinical response. J Natl Cancer Inst 1991;83:932-937.
5. Arienti F, Belli F, Rivoltini L, Gambacorti-Passerini C, Furlan L, Mascheroni L, Prada A, Rizzi M, Marchesl E, Vaglini M, Parmiani G, Gascinelli N Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2. Cancer Immunol Immunother 1993;36:315-322.
6. Topalian SL, Muul LM, Solomon D, Rosenberg SA: Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 1987;102:127-141.
7. Dudley ME Cell transfer therapy: Basic principles and preclinical studies; in Rosenberg SA (ed): Principles and Practice of the Biologic Therapy of Cancer. Philadelphia, LippincottAVilliams&Wilkins, 2000, pp 305-321.
8. Peoples GE, Schoof DD, Ravan Andrews JV, Goedegebuure PS, EberIeinTJ:T-cell recognition of ovarian cancer. Surgery 1993;l 14:227-234.
9. Dadmarz RD, Ordoubadi A, Mixon A, Thomson CO, Barracchini KC, Hijazi YM, Steller MA, Rosenberg SA, Schwartzentruber DJ Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in a MHC class IIrestricted fashion. Cancer J Sci Am 19962:263-272.
10. Heo DS, Whiteside TL, Kanbour A, Heberman RB Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKHl)-positive recombinant IL-2 activated cultures of lymphocytes infiltrating ovarian tumors. J Immunol 1988;140:4042-4049.
11. Freedman RS, Tomasovic B, Templin S, Atkinson EN, Kudelka A, Edwards CL, Platsoucas CD Largescale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Methods 1994;197:14S-160.
12. Melichar B, Nash MA, Lenzi R, Platsoucas CD, Freedman RS Expression of costimulatory molecules CD80 and CDS6 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumor infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin Exp Immunol 2000;119:19-27.
13. Kono K, Ichihara F, Izuka H, Sekikawa T, Matsumoto Y Differences in the recognition of tumor-specific CD8+ T cells derived from solid tumor, metastatic lymph nodes and ascites in patients with gastric cancer. Int J Cancer 1997;71:978-981.
14. Savary CA, Grazziutti ML, Melid, J B, Przepiorka D, Freedman RS, Cowart RE, Cohen DM, Anaissie EJ, Woodside DG, Mclntyre BW, Pierson DL, Pellis NR, Rex JH Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients. Cancer Immunol Immunother 1998;45:234-240.
15. Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin-2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinomatosis. Clin Cancer Res 2000;6:226S-2278.
16. Monteneiro J, Batliwalla F, Ostrer H, Gregersen PK Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J Immunol 1996;156:3587-3590.
17. Schwartzentruber DJ, Ham SS, Dadmarz R, White DE, Yannelli JR, Steinberg SM, Rosenberg SA, Topalian SL In vitro predictors of therapeutic re-sponse in melanoma patients receiving tumor-infiltrating lymphocytes and interIeukin-2. J Clin Oncol 1994;12:1475-1483.
18. Runyon BA, Hoefs JC, Morgan TR Ascitic fluid in malignancy-related ascites. Hepatology 1988;8: 1104-1109.
19. Novak TJ, Farber D, Leitberg D, Hong SC, Johnson P, Bottomly K Isoforms of the transmembrane tyrosine phosphatase CD45 differentially affect T cell recognition. Immunity 1994;1:109-119.
20. Reibnegger G, Fuchs D, Fuith LC, Hausen A, Werner ER.Wemer-Felmayer G, Wächter H: Neopterin as a marker for activated cell-mediated immu- ' nity: Application in malignant disease. Cancer Detect Prev 1991;15:483-490.
21. De Vita F, Orditura M, Galizia G, Romano C, Infusino S, Auriemma A, Lieto E, Catalano G Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer 1999; 86:1936-1943.
22. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P.Troppmair J, Wächter H: Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984:160:310-316.
23. Loercher AE, Nash MA, Kavanagh JJ, Platsoucas CD, Freedman RS Identification of an IL-10 producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 1999; 163:6251-6260.
24. Modolell M, Corraliza IM, Link F, Soler G, Eichman K Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrowderived macrophages by TH1 and TH2 cytokines. Eur J Immunol 199525:1101-1104.
25. Barnaba V, Watts C, de Boer M, Lane P, Lanzavecchia A Professional presentation of antigen by activated human T cells. Eur J Immunol 199424: 71-75.
26. Pichler WJ, Wyss-Coray T T cells as antigen-presenting cells. Immunol Today 1994;15:312-315.